Vax 2.0, Here We Go: Moderna Announces “Human Trials” of New Hybrid Flu-Covid Vaccine Are Officially Underway – Future “Triple-Threat” Vaccine “in the Works”

On Sunday, Moderna’s Chief Medical Officer Dr. Paul Burton announced the vaccine maker had officially kicked off phase 1 “human trials” for its new two-in-one Flu-Covid jab.

According to Burton, who spoke exclusively with 9News Australia, phase one clinical trials for the hybrid vaccine are currently underway and progressing on schedule, with the new treatment expected to be rolled out between late 2023 and early 2024.

From 9News:

“A phase one trial of a combination flu and Covid vaccine is currently underway. Moderna plans to have that vaccine ready by next year or by early 2024.”

Moderna’s CMO also announced that the company is currently working on a “triple-threat” vaccine that will be made available sometime in 2024 or 2025, following the rollout of the hybrid ‘Flu-Rona’ vaccine. The third-generation treatment will also target a lung infection called respiratory syncytial virus (RSV), which is a common, contagious virus that causes infections of the respiratory tract, according to the CDC.

Just like with Covid, RSV has an extremely low mortality rate for the vast majority of people. But, the sCiEnCe says we need another experimental vaccine – and you must take it.

Initial “human trials” for this triple vaccine are also expected to begin by the end of this year.

Burton explained: